- November 11, 2011 - S-Nitrosoglutathione Reductase Inhibitors for the Prevention and Treatment of Experimental Colitis
- August 28, 2011 - Structure – Activity Relationships of Pyrrole Based S-Nitrosoglutathione Reductase Inhibitors – Carboxamide Modification
- July 14, 2011 - Heterozygous Deletion of S-Nitrosoglutathione Reductase in Mice Does Not Increase Nitrosative Inactivation of O6-Alkylguanine-DNA Alkyltransferase or Diethylnitrosamine-induced Hepatocarcinogenesis
- May 3, 2011 - Oral S-Nitrosoglutathione Reductase Inhibitors Attenuate Pulmonary Inflammation and Decrease Airspace Enlargement in Experimental Models of COPD
- March 27, 2011 - Discovery of S-nitrosoglutathione reductase inhibitors as potential agents to treat asthma, COPD and IBD
More posters
|
GSNOR S-Nitrosoglutathione Reductase (GSNOR)
S-Nitrosoglutathione reductase (GSNOR) regulates S-nitrosothiols (SNOs) and nitric oxide (NO) in vivo through catabolism of S-nitrosoglutathione (GSNO). GSNOR, through its regulation of intracellular GSNO levels, plays a pivotal role in pulmonary, gastrointestinal, and cardiovascular physiology and pathophysiology.
GSNOR has emerged as an attractive therapeutic target for cystic fibrosis and other inflammatory lung diseases. N30 Pharma has developed the first small molecule inhibitors of GSNOR to reach clinical development.
In experimental models of human lung disease, N30 Pharma has demonstrated that GSNOR inhibitors:
- Prevented neutrophilic infiltration into the lung in cigarette smoke induced models of COPD
- Preserved lung architecture in an elastase-induced mouse model of emphysema as shown in Figures 1 and 2 below
- Decreased eosinophilic infiltration and inflammatory biomarker levels in bronchoalveolar lavage fluid, NFκB DNA binding activity in the lung, and airway hyperresponsiveness in an ovalbumin model of asthma
- Preserved mucosal integrity and decreased neutrophil and macrophage mediated colon necrosis, edema, and inflammation in a model of inflammatory bowel disease
 Fig 1. Oral vehicle  Fig 2. Oral GSNOR inhibitor
|
- January 24, 2013 - Pharmacological Inhibition of S-Nitrosoglutathione Reductase Improves Endothelial Vasodilatory Function in Rats in vivo
- December 28, 2012 - ADH IB Expression, but Not ADH III, Is Decreased in Human Lung Cancer
- February 15, 2012 - Mechanism of Inhibition for N6022, a First-in-Class Drug Targeting GSNOR
- January 13, 2012 - Structure–activity relationship of pyrrole based GSNOR inhibitors
- August 25, 2011 - Preclinical 28-Day Inhalation Toxicity Assessment of S-Nitrosoglutathione
- July 26, 2011 - Discovery of potent and novel GSNOR inhibitors devoid of cytochrome P450 activities
- April 19, 2011 - Structure–activity relationships of pyrrole based GSNOR inhibitors: Pyrrole regioisomers and propionic acid replacement
|
